{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "ORPHAN DRUG|Designated|Treatment of immune thrombocytopenic purpura (ITP)" in comments (approximate match)
Showing 1 - 2 of 2 results
Status:
Investigational
Source:
NCT04562766: Phase 3 Interventional Active, not recruiting Immune Thrombocytopenia
(2020)
Source URL:
Class:
MIXTURE
Status:
US Approved Rx
(2023)
Source:
BLA761286
(2023)
Source URL:
First approved in 2023
Source:
BLA761286
Source URL:
Class:
PROTEIN
